Valuation: Allogene Therapeutics, Inc.

Market Cap 453M 402M 373M 339M 640M 42.95B 650M 4.48B 1.76B 22.42B 1.7B 1.66B 71.46B P/E 2026 *
-2.17x
P/E 2027 * -2.04x
Enterprise Value 256M 228M 211M 192M 362M 24.3B 368M 2.54B 994M 12.68B 961M 941M 40.43B EV / Sales 2026 *
75.3x
EV / Sales 2027 * 25x
Free-Float
88.97%
Yield 2026 *
-
Yield 2027 * -
1 day-2.24%
1 week-10.27%
Current month-18.12%
1 month-22.49%
3 months-26.82%
6 months-44.73%
Current year-4.38%
1 week 1.22
Extreme 1.22
1.46
1 month 1.22
Extreme 1.22
1.74
Current year 1.22
Extreme 1.22
4.46
1 year 1.04
Extreme 1.04
4.46
3 years 0.86
Extreme 0.8621
5.78
5 years 0.86
Extreme 0.8621
20.75
10 years 0.86
Extreme 0.8621
55
Manager TitleAgeSince
Chief Executive Officer 48 01/07/2026
Director of Finance/CFO 61 16/10/2023
Chief Tech/Sci/R&D Officer 49 28/02/2025
Director TitleAgeSince
Chairman 76 01/11/2017
Director/Board Member 66 01/06/2018
Director/Board Member 49 01/11/2017
Date Insider Type Main position Quantity % Market Cap. Importance
21/8/26 Sell

Compliance Officer

-29,697 0.0086%
1/7/26 Free

Chief Executive Officer

610,720 0.1769%
18/6/26 Free

Director

95,400 0.0276%
Change 5-day change 1-year change 3-year change Capi.($)
-2.24%-10.27%+3.15%-59.57% 453M
-6.60%-8.56%+42.79%+64.16% 65B
-4.09%-0.11%+2.31%+54.81% 51.19B
+0.03%+5.56%+10.18%+41.75% 51.2B
-1.53%+2.70%+29.72%+34.13% 43.93B
-1.34%+4.12%+16.05%+112.18% 41.96B
-5.97%-6.22%+258.21%+421.57% 38.14B
+6.53%+8.02%+15.74%+53.94% 33.24B
-0.90%-10.49%+31.48%-1.63% 25.2B
-2.76%-9.54%-16.53%-9.55% 22.03B
Average -1.89%-2.53%+39.31%+71.18% 37.24B
Weighted average by Cap. -2.30%-1.22%+43.51%+88.40%

Financials

2026 *2027 *
Net sales 3.4M 3.02M 2.8M 2.55M 4.81M 323M 4.89M 33.67M 13.2M 168M 12.76M 12.49M 537M 12.09M 10.74M 9.96M 9.06M 17.1M 1.15B 17.37M 120M 46.93M 599M 45.36M 44.39M 1.91B
Net income -185M -165M -153M -139M -262M -17.57B -266M -1.83B -719M -9.17B -695M -680M -29.23B -220M -195M -181M -165M -311M -20.86B -316M -2.18B -854M -10.89B -825M -807M -34.71B
Net Debt -197M -175M -162M -147M -278M -18.65B -282M -1.95B -763M -9.73B -738M -722M -31.03B -150M -133M -124M -113M -212M -14.25B -216M -1.49B -583M -7.44B -564M -552M -23.71B
Projected Income Statement - Annual - Allogene Therapeutics, Inc.
Logo Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
Employees
151
Date Price Change Volume
16/10/26 US$1.310 -2.24% 4,919,065
15/10/26 US$1.340 +3.08% 4,515,192
14/10/26 US$1.300 +0.78% 7,736,868
13/10/26 US$1.290 -7.86% 6,543,528
12/10/26 US$1.400 -4.11% 4,316,472
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Allogene Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
1.310USD
Average target price
9.000USD
Spread / Average Target
+587.02%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Allogene Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ALLO Stock